Approval is based on results of a phase III clinical trial involving 3,370 patients life sciences sweden previously mentioned in . According to the study, empagliflozin (Guardians) had a 25 percent lower risk of cardiovascular death or hospitalization from heart failure compared to placebo plus standard treatment for heart failure patients with impaired left ventricular function with or without type 2 diabetes.
About half of patients with heart failure have impaired left ventricular function, which means that the heart has reduced pumping ability.
– Heart failure is a common and serious condition. So it is gratifying that empagliflozin is now approved for the treatment of heart failure with impaired left ventricular function, thus giving us another important therapeutic alternative for this vulnerable group of patients, he says. Lars LundD., chief medical officer at Tema Cardiovascular and Neurology, Karolinska University Hospital, and professor at Karolinska Institutet, in a press release from pharmaceutical company Boehringer Ingelheim.
Empagliflozin is an SGLT2 inhibitor previously approved for the treatment of type 2 diabetes in adults whose disease cannot be controlled by diet and exercise alone.